Therapeutic nanobodies against SARS-CoV-2 and other pathogenic human coronavirusesReview Published on 2024-05-312024-09-05 Journal: Journal of Nanobiotechnology [Category] update2024, [키워드] MERS-CoV pathogenic coronaviruses Receptor-binding domain SARS-CoV SARS-CoV-2 Spike protein therapeutic antibodies [DOI] 10.1186/s12951-024-02573-7 PMC 바로가기 [Article Type] Review
10th antibody industrial symposium: new developments in antibody and adoptive cell therapiesMeeting Report Published on 2023-05-152024-09-05 Journal: mAbs [Category] update2024, [키워드] antibody engineering Antibody industrial symposium antibody-related molecules Biotherapeutics cell-based therapies congress intellectual property research translation into clinic therapeutic antibodies [DOI] 10.1080/19420862.2023.2211692 PMC 바로가기 [Article Type] Meeting Report
Sequence enrichment profiles enable target-agnostic antibody generation for a broad range of antigensarticle Published on 2023-05-092024-09-05 Journal: Cell Reports Methods [Category] update2024, [키워드] Biomarkers Computational biology mathematical modeling phage display phenotypic antibody discovery specificity predictions therapeutic antibodies [DOI] 10.1016/j.crmeth.2023.100475 PMC 바로가기 [Article Type] article
Repertoires of SARS-CoV-2 epitopes targeted by antibodies vary according to severity of COVID-19코로나19 중증도에 따라 항체 표적 SARS-CoV-2 에피토프 레퍼토리 달라Article Published on 2022-12-012022-09-11 Journal: Virulence [Category] COVID19(2023년), SARS, 진단, 치료법, [키워드] antibodies antibody Antigen association Asymptomatic asymptomatic individual asymptomatic infection Betacoronavirus Community convalescent correlated COVID-19 COVID-19 severity develop diagnosed diagnostics disease severity domains Epitopes Evidence evidence of finding FIVE five groups HKU1 Hospitalization IgG IgGs Immunity immunogenic immunogenic peptide individual Infection less MERS-CoV nucleocapsid protein Nucleocapsid proteins OC43 participant pathogenic pathogenic mechanisms peptide peptide array peptides pilot study predicted Protein RBDs reaction Receptor binding domain Region repertoire SARS-CoV RBD SARS-CoV RBDs SARS-CoV-2 SARS-CoV-2 epitope SARS-CoV-2 epitopes seroconverted Seroprevalence severity severity of COVID-19 symptomatic symptomatic COVID-19 symptomatic infection therapeutic therapeutic antibodies Vaccines Viral with COVID-19 without symptoms [DOI] 10.1080/21505594.2022.2073025 PMC 바로가기 [Article Type] Article
Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variantsArticle Published on 2022-11-012022-11-15 Journal: Cell Reports [Category] SARS, 변종, 진단, [키워드] Analysis antibodies antibody Beta breadth complementary conserved CP: Immunology CP: Microbiology Efficacy Hamster model human monoclonal antibodies immune Immune escape in vivo interact monoclonal antibody mutations neutralization neutralize Neutralizing activity omicron Omicron sublineages BA.1., BA.2, BA.2.12.1, and BA.4 overcome potent Protective provide raise reduced SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants Spike protein Spread the receptor-binding domain the SARS-CoV-2 therapeutic therapeutic antibodies therapeutic efficacy Vaccine variant variants variants of concern [DOI] 10.1016/j.celrep.2022.111528 PMC 바로가기
Evolution of Anti-SARS-CoV-2 Therapeutic AntibodiesArticle Published on 2022-08-282022-11-15 Journal: International Journal of Molecular Sciences [Category] SARS, 변종, 진단, [키워드] antibodies antibody approval authorization bamlanivimab bebtelovimab Casirivimab caused Characteristics cilgavimab claimed conserved COVID-19 COVID-19 pandemic Critical Diseases drug Efficacy EMA Emergency epitope etesevimab EUA European Evolution of SARS-CoV-2 FDA Features food HCDR3 help Imdevimab information Interaction Medicine Modification neutralization nine Prevent RBD regdanvimab regions residue SARS-CoV-2 somatic mutations Sotrovimab the receptor-binding domain therapeutic therapeutic antibodies Tixagevimab treat variants of concern viral infection VoC VOCs [DOI] 10.3390/ijms23179763 PMC 바로가기
SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodiesSARS-CoV-2 Omicron 하위 계통은 유사한 세포 진입을 나타내지만 치료 항체에 의한 차등 중화를 나타냅니다.Article Published on 2022-08-102022-09-11 Journal: Cell Host & Microbe [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] ACE2 antibodies antibody Antibody-mediated neutralization BNT162b2 booster vaccination cell entry cilgavimab comparable COVID-19 COVID-19 therapy Efficiency eight evade exhibit FUSE homologous or heterologous neutralization neutralized omicron Omicron variant SARS-CoV-2 Seven Sotrovimab spike susceptibility target cell target cells therapeutic therapeutic antibodies therapy Transmissibility Treatment vaccination Vaccine vaccine-induced antibodies vaccine-induced antibody variant of SARS-CoV-2 [DOI] 10.1016/j.chom.2022.04.017 PMC 바로가기 [Article Type] Article
Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5SARS-CoV-2 오미크론 하위 변이체 BA.2.12.1, BA.4 및 BA.5에 의한 항체 회피Article Published on 2022-08-012022-09-11 Journal: Nature [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] Analysis antibodies antibody antigenic bebtelovimab breakthrough infections Clinical use COVID-19 vaccine COVID-19 vaccines dominant Efficacy evade facilitate individual lead Lineage Mutation Neutralizing antibodies omicron raise receptor Receptor-binding domain Region residue SARS-CoV-2 sera South Africa Spike protein Spike proteins the receptor-binding domain the United State therapeutic therapeutic antibodies United States vaccine breakthrough infections Viral yielding [DOI] 10.1038/s41586-022-05053-w PMC 바로가기 [Article Type] Article
In vitro activity of therapeutic antibodies against SARS-CoV-2 Omicron BA.1, BA.2 and BA.5SARS-CoV-2 Omicron BA.1, BA.2 및 BA.5에 대한 치료 항체의 시험관 내 활성Article Published on 2022-07-232022-09-11 Journal: Scientific Reports [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] active against Alter antibody cilgavimab D614G delta variant European Fold change growth less Lineage lineage B.1 monoclonal antibodies monoclonal antibody Mutation neutralising not enhanced omicron reduction replacement SARS-CoV-2 significantly Sotrovimab Spectrum spike glycoprotein strain therapeutic therapeutic antibodies Tixagevimab union variant of SARS-CoV-2 variants [DOI] 10.1038/s41598-022-16964-z PMC 바로가기 [Article Type] Article
A broad and potent neutralization epitope in SARS-related coronavirusesSARS 관련 코로나바이러스의 광범위하고 강력한 중화 에피토프Article Published on 2022-07-192022-09-11 Journal: Proceedings of the National Academy of Sciences of [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] ACE2 acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 antibodies antibody B.1.1.529 benefit conserved conserved epitope coronavirus CR3022 cross-neutralizing cross-neutralizing antibody Effectiveness elicited epitope high potency Interaction NAbs natural infection neutralization neutralize Neutralizing antibodies neutralizing antibody omicron RBS receptor binding site reduced respiratory SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants SARS-related coronavirus SARS-related coronaviruses therapeutic therapeutic antibodies vaccination Vaccine variants variants of concern VOCs X-ray X-ray crystallography [DOI] 10.1073/pnas.2205784119 PMC 바로가기 [Article Type] Article